This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
BMYNegative Net Change AMGNNegative Net Change SRPTPositive Net Change PCRXNegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
by Zacks Equity Research
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
BMYNegative Net Change FOLDNegative Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
by Zacks Equity Research
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
FOLDNegative Net Change ANIPNegative Net Change NCNANegative Net Change RLYBNegative Net Change
biotechs
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
DVAXNegative Net Change BAYRYPositive Net Change ADMANegative Net Change RXRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
JAZZNegative Net Change EBSNegative Net Change
biotechs cannabis medical pharmaceuticals
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
by Zacks Equity Research
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
DVAXNegative Net Change BAYRYPositive Net Change PCRXNegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
by Zacks Equity Research
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
DVAXNegative Net Change BAYRYPositive Net Change ADMANegative Net Change RYTMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
by Zacks Equity Research
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
PFENegative Net Change BMRNNegative Net Change ADMANegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
by Zacks Equity Research
With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.
VRTXNegative Net Change MRNANegative Net Change ANIPNegative Net Change ETNBPositive Net Change
biotechs medical messenger-rna pharmaceuticals
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
by Zacks Equity Research
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
ANIPNegative Net Change CTMXNegative Net Change ALLONegative Net Change ETNBPositive Net Change
biotechs crispr medical pharmaceuticals
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
GILDNegative Net Change BMRNNegative Net Change FOLDNegative Net Change ADMANegative Net Change KRYSNegative Net Change
biotechnology biotechs medical pharmaceuticals
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
BAYRYPositive Net Change CYTKNegative Net Change ADMANegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
by Zacks Equity Research
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
BIAFNegative Net Change
biotechnology biotechs earnings medical
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
AZNNegative Net Change DVAXNegative Net Change JAZZNegative Net Change KRYSNegative Net Change
biotechs
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change AMGNNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals vaccines
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
by Zacks Equity Research
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
DVAXNegative Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
by Zacks Equity Research
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
DVAXNegative Net Change AMGNNegative Net Change JAZZNegative Net Change KRYSNegative Net Change
biotechs
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
by Zacks Equity Research
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
DVAXNegative Net Change BAYRYPositive Net Change PCRXNegative Net Change CORTNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
by Zacks Equity Research
The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient
RHHBYNegative Net Change SRPTPositive Net Change ANIPNegative Net Change CTMXNegative Net Change
biotechs gene-therapy medical pharmaceuticals
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.
BIIBNegative Net Change LLYNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
by Zacks Equity Research
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
REGNNegative Net Change RHHBYNegative Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
by Zacks Equity Research
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
NVSPositive Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
by Zacks Equity Research
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
BMRNNegative Net Change ANIPNegative Net Change CTMXNegative Net Change ETNBPositive Net Change
biotechs medical
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
DVAXNegative Net Change BAYRYPositive Net Change CORTNegative Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
by Zacks Equity Research
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
SNYPositive Net Change BAYRYPositive Net Change CORTNegative Net Change NRIXNegative Net Change
biotechnology biotechs medical pharmaceuticals